OBJECTIVE To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates. DESIGN Post hoc analysis of four year, double blind Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study PARTICIPANTS 1617 men randomised to dutasteride or placebo with a prostate size >40 mL and baseline International Prostat...

We report the case of a 56-year-old man with a prostatic mass that extended into the rectal mucosa. He experienced constipation and anal bleeding for 6 months. He underwent surgical ablation for an approximately 5-cm, benign, subepithelial cystic mass in the rectum, which was adjacent to a 5-cm solid mass located on the prostatic gland seen on computed tomography and magnetic resonance imaging ...

A patient who was troubled by the persistent passage of prostatic calculi following transurethral prostatectomy is reported. The pathogenesis of these calculi is postulated.

Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. The active compounds of the drug have not been identified, and determining the plasma concentration of the drug is, therefore, not possible. Because there are conflicting results on the efficacy of this drug, we aimed to investigate its effect on prostate cell growth...

Background and objectives: Hemorrhoids is the most prevalent rectal disease which is defined as enlargement of ano-rectal cushions.  Intensified pressure on vascular plexus of hemorrhoids seems playing a chief role in the development of hemorrhoids. Hemorrhoidectomy is an important surgery to relieve discomforts of patients that suffer from symptomatic hemorrhoids. This review ...

......................................................................... 5 LIST OF ORIGINAL PAPERS............................................. 7 ABBREVIATIONS............................................................... 9 INTRODUCTION................................................................ 11 Background...................................................................... 12 Benign ...